KDM1A and prostate adenocarcinoma: We used the catalytic inhibitors GSK-LSD1 and GSK-2879552 (20) and an allosteric inhibitor SP2509 (26) — which we previously showed to be effective in blocking LSD1’s noncatalytic function in PRAD cells (13) — in a panel of PRAD and NEPC cell lines (Figure 2A).